Financial

News

Falling flu vaccine sales in US stall CSL's Seqirus spinout

CSL says flu vaccination rates in the US are expected to fall 12% to 14% this year, and have scuppered its plan to spin out its vaccines unit Seqirus.

News

Novartis' new drugs outweigh Entresto decline in Q3

Now feeling the impact of generic competition on its top product Entresto in the US, Novartis is still looking for pipeline-building deals, says CEO.

News

Stada revives talk of an IPO – if conditions improve

Germany's Stada has said it may make another attempt to seek a public listing in the autumn, after delaying its plans earlier this year.

News

CSL will slash headcount and hive off vaccine business

Facing declines in flu vaccination rates in the US, CSL will spin out its vaccine unit as part of a wider restructuring that will claim 3,000 jobs.

News

Iovance cuts staff on slower cell therapy sales growth

Iovance will slash 19% of its headcount in a restructuring that follows slower-than-expected sales growth for melanoma cell therapy Amtagvi.

News

Lilly weakens on oral weight-loss drug data

Shares in Eli Lilly have come under pressure after reporting the results of a phase 3 trial of oral weight-loss candidate orforglipron.

Falling flu vaccine sales in US stall CSL's Seqirus spinout

Novartis' new drugs outweigh Entresto decline in Q3

Stada revives talk of an IPO – if conditions improve

CSL will slash headcount and hive off vaccine business

Iovance cuts staff on slower cell therapy sales growth

Lilly weakens on oral weight-loss drug data

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Financial

Editor's Picks